514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797634215923154944 |
|---|---|
| author | Jessica Yu Ariel Chen Michihisa Umetani Courtney Le Li-Fen Lee Kan Lu |
| author_facet | Jessica Yu Ariel Chen Michihisa Umetani Courtney Le Li-Fen Lee Kan Lu |
| author_sort | Jessica Yu |
| collection | DOAJ |
| first_indexed | 2024-03-11T12:04:38Z |
| format | Article |
| id | doaj.art-539af10822d147a68caa6c0b6d1cf147 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T12:04:38Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-539af10822d147a68caa6c0b6d1cf1472023-11-07T16:40:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0514514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapyJessica Yu0Ariel Chen1Michihisa Umetani2Courtney Le3Li-Fen Lee4Kan Lu52School of Population and Public Health, University of British Columbia, CanadaWilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA1Apeximmune Therapeutics, Mountain View, CA, USA1Apeximmune Therapeutics, Mountain View, CA, USA2Apeximmune Therapeutics Inc, Palo Alto, CA, USA1Apeximmune Therapeutics, Mountain View, CA, USA |
| spellingShingle | Jessica Yu Ariel Chen Michihisa Umetani Courtney Le Li-Fen Lee Kan Lu 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy Journal for ImmunoTherapy of Cancer |
| title | 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy |
| title_full | 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy |
| title_fullStr | 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy |
| title_full_unstemmed | 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy |
| title_short | 514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy |
| title_sort | 514 development of aim 104 a potential best in class pan allele anti sirpα antibody for anti tumor therapy |
| work_keys_str_mv | AT jessicayu 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy AT arielchen 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy AT michihisaumetani 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy AT courtneyle 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy AT lifenlee 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy AT kanlu 514developmentofaim104apotentialbestinclasspanalleleantisirpaantibodyforantitumortherapy |